Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.96−0.10 (-1.24%)
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Novavax price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Novavax's price to sales ratio was 4.0× on Nov 11, 2026, against 1.1× a year earlier. Over the last 5 years it ranged from 0.3× to 9.0×, with a median of 1.3×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 4.0× | +2.9 |
| 2025 | Dec 31, 2025 | 1.0× | −0.4 |
| 2024 | Dec 31, 2024 | 1.5× | +0.9 |
| 2023 | Dec 29, 2023 | 0.5× | +0.1 |
| 2022 | Dec 30, 2022 | 0.4× | −8.5 |
| 2021 | Dec 31, 2021 | 9.0× | −25.3 |
| 2020 | Dec 31, 2020 | 34.3× | +27.9 |
| 2019 | Dec 31, 2019 | 6.4× | −11.9 |
| 2018 | Dec 31, 2018 | 18.3× | +3.6 |
| 2017 | Dec 29, 2017 | 14.7× | −6.9 |
| 2016 | Dec 30, 2016 | 21.6× | −39.4 |
| 2015 | Dec 31, 2015 | 61.0× | +17.7 |
| 2014 | Dec 31, 2014 | 43.3× | −5.1 |
| 2013 | Dec 31, 2013 | 48.4× | +37.3 |
| 2012 | Dec 31, 2012 | 11.1× | – |
See a number that looks wrong?